Drug Trial Radar · NCT02273726
Study to Evaluate the Efficacy and Safety of Roxadustat in the Treatment of Anemia in Participants With ESRD on Stable Dialysis
Last checked: Nov 19, 2026Latest source record: Oct 29, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
741
Actual
Start
Jan 15, 2015
Primary completion
Sep 19, 2018
Study completion Sep 19, 2018
Sponsor
- Lead sponsor
- Kyntra BioIndustry
- Sponsor type
- Industry
- Collaborators
- Astellas Pharma Europe B.V.; AstraZeneca
- First posted
- Oct 24, 2014
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study is to evaluate the efficacy and safety of roxadustat compared with active control (epoetin alfa) for the maintenance treatment of anemia in participants with ESRD on dialysis.
Conditions
- CKD Anemia in Stable Dialysis Patients
Interventions
Epoetin AlfaDrug
Epoetin alfa will be administered per dose and schedule specified in the arm.
RoxadustatDrug
Roxadustat will be administered per dose and schedule specified in the arm.
Primary outcomes
What the sponsor says the trial is designed to measure.
- US (FDA) Submission: Mean Hb Change From Baseline to The Average Level During The Evaluation Period (Weeks 28 to 52), Regardless of Rescue TherapyTime frame: Baseline (Day 1, Week 0), Weeks 28 to 52
- Ex-U.S. Submission: Mean Hb Change From Baseline to the Average Weeks 28 to 36, Without Having Received Rescue Therapy Within 6 Weeks Prior to and During This 8-Week Evaluation Period for Participants Enrolled Under the Original ProtocolTime frame: Baseline (Day 1, Week 0), Weeks 28 to 36
Locations
76 sites in 2 countries. Site status is shown where the registry gives one.
Research Center
Phoenix, Arizona
Research Center
Pine Bluff, Arkansas
Research Center
Chula Vista, California
Research Center
Chula Vista, California
Research Center
La Mesa, California
Research Center
Long Beach, California
Research Center
Long Beach, California
Research Center
Los Angeles, California
Research Center
Northridge, California
Research Center
Ontario, California
Research Center
Roseville, California
Research Center
San Diego, California
Research Center
San Dimas, California
Research Center
San Gabriel, California
Research Center
Whittier, California
Research Center
Coral Springs, Florida
Research Center
Lauderdale Lakes, Florida
Research Center
Miami, Florida
Research Center
Miami, Florida
Research Center
Pembroke Pines, Florida
Research Center
Tampa, Florida
Research Center
Albany, Georgia
Research Center
Meridian, Idaho
Research Center
Shreveport, Louisiana
Research Center
Springfield, Massachusetts
Research Center
Detroit, Michigan
Research Center
Detroit, Michigan
Research Center
Pontiac, Michigan
Research Center
Brookhaven, Mississippi
Research Center
Columbus, Mississippi
Research Center
Gulfport, Mississippi
Research Center
Tupelo, Mississippi
Research Center
Creve Coeur, Missouri
Research Center
Kansas City, Missouri
Research Center
Saint Ann, Missouri
Research Center
St Louis, Missouri
Research Center
Portsmouth, New Hampshire
Research Center
North Brunswick, New Jersey
Research Center
Albuquerque, New Mexico
Research Center
Gallup, New Mexico
Showing 40 of 76 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.